Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia - Elhilali, MM; Pommerville, P; Yocum, RC (J Urol, 2013)
et al.